APOA1 and coronary artery disorder: ApoA-IM has been studied extensively with regard to effects on atherosclerosis, including infusion and genetic expression in animals [8,9] and even in a clinical trial of repeated intravenous infusion of an a ApoA-IM /phospholipid complexes in patients with CHD [10].